CRISPR Reagent Design Professors and Supervisors

Mathias Christmannمشاهده پروفایل

استاد

Free University of BerlinGermany

Prof. Dr. Mathias Christmann is a faculty member at the Institute of Chemistry and Biochemistry, Freie Universität Berlin , leading the research group in Organic Chemistry . His work focuses on strategic and methodological challenges in synthetic chemistry, particularly in total synthesis, organocatalysis, and renewable resource transformations. Position: Professor Contact: mathias.christmann@fu-berlin.de Location: Takustr. 3, Room 24.16, 14195 Berlin Research Interests include: Natural product-inspired small molecule synthesis for biological pathway modulation Minimizing C-C bond formations through selective functionalization of terpene building blocks Organocatalytic and metal-catalyzed reactions in multistep sequences Flow chemistry applications for scalable and sustainable synthesis Biological evaluation of TRPC channel agonists/antagonists for cancer therapy Publication Trends highlight expertise in total synthesis of complex terpenoids, organocatalysis for stereocontrolled reactions, flow chemistry for late-stage transformations, and TRPC4/5 channel modulation in renal cancer studies. His group pioneers asymmetric desymmetrization , photo-oxidation protocols , and electrosynthesis methods with minimal reagent waste. Advisees include PhD candidates Jan-Hendrik Dickoff , Mayar Elbendary , Nadine Kreidt , Tobias Olbrisch , Kamar Shakeri , and Zhen Wang , focusing on terpene-based drug discovery and catalytic reaction design.

پروفایل رسمی دانشگاه

Bill Luمشاهده پروفایل

استادیار

Santa Clara UniversityUnited States

Bill Lu is an Assistant Professor at Santa Clara University's School of Engineering, Department of Bioengineering. With dual expertise in medicine (MD from Shanghai Medical University) and Biochemistry and Human Genetics (PhD from University of Manitoba), he focuses on developing genetic tools for treating complex diseases. MD: Shanghai Medical University, Clinical Medicine PhD: University of Manitoba, Biochemistry and Medical Genetics BS: University of Manitoba, Computer Sciences His research spans Nanomedicine (genetic disease, Alzheimer's, cancer), Targeted Drug Delivery (exosome-based systems), Gene Therapy (viral/non-viral delivery), and Molecular Imaging (fluorescence/bioluminescence probes). Recent publications highlight trends in exosome engineering, genome editing, and therapeutic vesicle design. 2023 Teaching Excellence Award 2021 Research Excellence Award 2013 Technology Innovation Award 2004 Distinguished PhD Dissertation Award He has filed 4 patents, served on editorial boards, and advised students through courses like Molecular and Cell Biology and Genome Engineering. His work bridges academic research and industry applications in biotechnology.

پروفایل رسمی دانشگاه

Shana Kelleyمشاهده پروفایل

استاد

Northwestern UniversityUnited States

Shana Kelley is a Professor in the Department of Chemistry at Northwestern University's Weinberg College of Arts & Sciences, with joint appointments in Biomedical Engineering and Biochemistry. As President of the Chan Zuckerberg Biohub Chicago, she leads multidisciplinary research developing tools for disease diagnosis and therapy, including biomolecular sensors, phenotypic screening platforms, and molecular delivery vectors. Her group utilizes CRISPR, nanoscale cytometry, and electrochemical techniques. Research focuses include reagent-free biomolecular analysis, tumor-infiltrating lymphocyte recovery, and aptamer selection for programmable binding affinities. Prof. Kelley directs three active companies and mentors trainees who hold positions at top universities globally. Her honors include the 2023 National Academy of Inventors election and the 2022 Guggenheim Fellowship. Recent publications highlight innovations in continuous inflammation monitoring, mitochondrial probes, and microfluidic immunomagnetic sorting for cancer therapeutics.

پروفایل رسمی دانشگاه

Antonio Delgado Gonzalezمشاهده پروفایل

پژوهشگر

Stanford UniversityUnited States

Antonio Delgado Gonzalez is a Postdoctoral Scholar in the Department of Microbiology and Immunology at Stanford University, affiliated with the Nolan Lab since 2022. His research bridges chemistry, immunology, and biomedical innovation through advanced proteomic and cytometric methodologies. PhD in Biochemistry (Universidad De Granada, 2019) MSc/BSc in Biomedical Sciences (Universidad De Granada) Delgado Gonzalez specializes in mass cytometry , single-cell proteomics , and host-microbiome interactions . His work develops novel reagents for live-cell barcoding and metabolic pathway discovery in diseases like ovarian cancer and infectious conditions. His publications demonstrate mastery in multi-omics integration and immunometabolism , particularly through innovations in spatial proteomics and metabolic pathway engineering . These studies have been featured in Nature Biomedical Engineering and Cell . Scientific Awards Predoctoral FPU Fellowship (2015-2019) Short-term Stay Fellowships (2017-2018) Delgado Gonzalez contributes to multimodal biomarker development and therapeutic target identification in immunosuppressive tumor environments. His ORCID profile highlights collaborations with leading researchers in mass spectrometry and cancer immunology .

پروفایل رسمی دانشگاه

Oline Eriksen Rioمشاهده پروفایل

پژوهشگر ارشد

University of OsloNorway

Oline Eriksen Rio is a Doctoral Research Fellow at the Norwegian Centre for Molecular Biology and Medicine (NCMM) , affiliated with the Faculty of Medicine at the University of Oslo. She is part of the Emma Haapaniemi Group focused on precision pediatrics and gene editing. BSc in Human Genetics from Trinity College Dublin MSc in Biomedicine from the University of Bergen Work experience in cancer genomics and diagnostics at Haukeland University Hospital, Bergen Her research spans molecular biology and CRISPR reagent design for translational medicine, particularly through large-scale CRISPR guide screening to address gene editing challenges in primary immunodeficiency disorders with patient-specific mutations. Her 2023 publication in European Urology Oncology explores HPV-associated penile cancer survival trends in a Norwegian cohort.

پروفایل رسمی دانشگاه

Eric T. Koolمشاهده پروفایل

استاد

Stanford UniversityUnited States

Eric T. Kool is a Professor in the Department of Chemistry at Stanford University , where he holds the George and Hilda Daubert Professorship. He is affiliated with interdisciplinary programs including Bio-X , Biophysics , Stanford Cancer Institute , and the Sarafan ChEM-H initiative. His research spans organic chemistry , chemical biology , and biophysics , focusing on designing molecular tools for nucleic acid analysis and manipulation. Key contributions include nonpolar nucleoside isosteres , rolling circle amplification , and fluorescent DNA/RNA probes . His work has enabled DNA replication studies without hydrogen bonding and RNA structure mapping in cellular environments. Recent publications emphasize RNA 2'-OH functionalization , oxidative DNA repair , and CRISPR-Cas9 regulation . His innovations in acylation chemistry and nucleic acid-based data storage highlight his interdisciplinary approach. Scientific Awards : Dreyfus Foundation Teacher-Scholar Award Alfred P. Sloan Foundation Fellowship ACS Arthur C. Cope Scholar Award ACS Pfizer Award Murray Goodman Prize ACS Breslow Award Fellow of AAAS Member of the American Academy of Arts and Sciences Kool has trained over 120 graduate students and postdoctoral researchers , with more than 35 securing academic positions. His lab’s 45 patents underpin five biotechnology companies, and he has delivered over 250 invited lectures globally. He is also an award-winning educator, twice receiving the Humanities & Sciences Dean's Award for Distinguished Teaching at Stanford for his sophomore organic chemistry courses.

پروفایل رسمی دانشگاه

Tim Luetkensمشاهده پروفایل

دانشیار

University of Maryland, BaltimoreUnited States

Tim Luetkens, MD is an Associate Professor at the University of Maryland School of Medicine , holding a primary appointment in the Department of Microbiology and Immunology . He also serves as Director of R&D at the Fannie Angelos Cellular Therapeutics GMP Laboratory , facilitating clinical translation of cellular immunotherapies. His research focuses on cellular immunotherapies and protein engineering , addressing critical challenges like immune escape, antigen loss, and off-target toxicity. Through technologies such as CRISPR , antibody phage display , and CAR/TCR engineering , his Cell Engineering Lab develops innovative solutions for hematologic and solid tumors. Recent publications highlight his work on CAR T cell affinity tuning , trogocytosis inhibition , and HLA modulation , with clinical applications in multiple myeloma , neuroblastoma , and Ewing sarcoma . Collaborations with the Fannie Angelos GMP Lab enable pediatric and adult cell therapy product development .

پروفایل رسمی دانشگاه

Jim Wellsمشاهده پروفایل

استاد

University of California, San FranciscoUnited States

Jim Wells is a Professor at the University of California San Francisco (UCSF), affiliated with the Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology. He founded the Small Molecule Discovery Center and served as Chair of Pharmaceutical Chemistry. His research focuses on cell surface proteomics, protein engineering, and targeted drug discovery. Education: BA in Biochemistry and Psychology from UC Berkeley (1973), PhD in Biochemistry from Washington State University (1979), and postdoctoral training at Stanford University. Wells’ research spans enzyme engineering, apoptosis, and drug development for cancer and neurodegenerative diseases. His lab employs mass spectrometry and affinity-directed technologies to map cell surface changes in disease states. Recent work includes CRISPRi screens for autism risk genes, hypoxia-induced proteomic remodeling in pancreatic cancer, and engineered proteins for genome editing. His publications highlight expertise in protein engineering, chemical biology, and cancer signaling. Awards include election to the National Academy of Sciences and the Chan Zuckerberg Biohub Investigator designation. Wells has secured significant NIH funding for projects related to proteolysis, signaling, and biomarker discovery. Scientific Awards: Damon M. Runyon Fellowship, Pfizer Award, Christian B. Anfinsen Award, and others. He has co-founded multiple biotech companies, including Genentech (1982), Sunesis Pharmaceuticals (1998), and EpiBiologics (recently), advancing therapeutic proteases, RAF inhibitors, and extracellular degraders.

پروفایل رسمی دانشگاه

Douglas Houstonمشاهده پروفایل

استاد

University of IowaUnited States

Douglas Houston is a Professor in the Department of Biology at the University of Iowa, where he also serves as Director of the Developmental Studies Hybridoma Bank (DSHB). He holds a PhD from the University of Miami. His research investigates vertebrate developmental mechanisms, with a focus on maternal signaling pathways, RNA localization, and cytoskeletal dynamics in Xenopus models. Key areas include cortical rotation, Wnt signaling activation, and the role of asymmetrically localized mRNAs in embryonic axis formation. His work spans Cell and Developmental Biology and Neurobiology , emphasizing molecular regulation of early embryogenesis. Research integrates genetic, biochemical, and imaging approaches to dissect mechanisms of dorsal axis specification and neural development. Recent studies explore antibody validation protocols to enhance biomedical research reproducibility. Houston directs the DSHB, a core facility supporting antibody-based research globally. The lab employs Xenopus laevis and Xenopus tropicalis for functional genomics, including CRISPR-based editing and maternal mRNA manipulation techniques.

پروفایل رسمی دانشگاه